Trials / Recruiting
RecruitingNCT06594991
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
A Phase 2 Study of Fianlimab, Cemiplimab, and Ipilimumab in Anti-PD-1 Refractory Melanoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fianlimab | Fianlimab IV given every three weeks |
| DRUG | Cemiplimab | Cemiplimab IV given every three weeks |
| DRUG | Ipilimumab | Ipilimumab will be give every 6 weeks continuously |
Timeline
- Start date
- 2024-09-10
- Primary completion
- 2027-09-01
- Completion
- 2027-09-01
- First posted
- 2024-09-19
- Last updated
- 2026-03-27
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06594991. Inclusion in this directory is not an endorsement.